At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Apr 2000 New profile
- 18 Apr 2000 Preclinical development for Cancer in USA (Unknown route)